Company: Abbott Laboratories
Ticker: ABT
Form: 10-K
Filed: 2026-02-20
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Abbott Laboratories's revenue in fiscal year 2025?
Question Type: value_lookup

Concept: RevenueFromContractWithCustomerExcludingAssessedTax
Answer (Numeric): 44328.0
Answer (Display): $44,328 million
Unit: USD millions

Evidence:
[{"chunk_id": "114", "equivalent_chunk_ids": ["114"], "section": "Consolidated Statement of Earnings", "supports": ["main"], "text": "(in millions except per share data)\nYear Ended December 31\nNet Sales\n44,328\n41,950\n40,109\nCost of products sold, excluding amortization of intangible assets\n19,319\n18,706\n17,975\nAmortization of intangible assets\n1,682\n1,878\n1,966\nResearch and development\n2,942\n2,844\n2,741\nSelling, general and administrative\n12,332\n11,697\n10,949\nTotal Operating Cost and Expenses\n36,275\n35,125\n33,631\nOperating Earnings\n8,053\n6,825\n6,478\nInterest expense\nInterest income\nNet foreign exchange (gain) loss\nOther (income) expense, net\nEarnings before Taxes\n8,466\n7,013\n6,664\nTaxes on Earnings\n1,942\n6,389\nNet Earnings\n6,524\n13,402\n5,723\nBasic Earnings Per Common Share\n3.73\n7.67\n3.28\nDiluted Earnings Per Common Share\n3.72\n7.64\n3.26\nAverage Number of Common Shares Outstanding Used for Basic Earnings Per Common Share\n1,741\n1,740\nDilutive Common Stock Options\nAverage Number of Common Shares Outstanding Plus Dilutive Common Stock Options\n1,748\n1,749\nOutstanding Common Stock Options Having No Dilutive Effect\nThe accompanying notes to consolidated financial statements are an integral part of this statement.\nAbbott Laboratories and Subsidiaries"}]

Derivation: